“Impact of monocyte-macrophage inhibition by ibandronate on graft and patient survival after kidney transplantation: a single center follow-up study over 15 years”

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010613

Enrollment

Registered

2016-09-28

Start date

2016-09-24

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evolution of renal function after kidney transplantation following medication with ibandronate N18.4

Interventions

Group 1: Treatment group: patients with ibandronate medication in the first post-transplant year, the intervention took has taken place from 1999-2000, this study seeks to retrospectively for 15 years

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: All participants of the initial prospective randomized trial: study time 1999-2000 Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, Strey C, Kirste G, Olschewski M, Reichelt A, Rump LC. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol 2001; 12: 1530-1537

Exclusion criteria

Exclusion criteria: lost to follow-up

Design outcomes

Primary

Measure	Time frame
retrospective evaluation of graft and patient survival data	—

Secondary

Measure	Time frame
renal transplant function 5, 10, 15 years after the intervention or transplantation, measurement of reanl function is based on creatinine levels and calculation of the eGFR (CKD-EPI formula)	—

Countries

Germany

Contacts

Public ContactPrzemyslaw Pisarski

Department Chirurgie, Klinik für Allgemein- und Viszeralchirurgie, Transplantationszentrum, Universitätsklinikum Freiburg

przemyslaw.pisarski@uniklinik-freiburg.de+49 761 270 27320

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026